Barr Pharmaceuticals Inc. (BRL)
|
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: |
Articles on Barr Pharmaceuticals Inc. (BRL)
54 articles
Filter by:
Latest Articles Most commented on articlesMost frequent authors on BRL
- SA Editor Eli Hoffmann(6)
- Mike Havrilla(6)
- Aaron F. Barkoff(5)
- Market Folly(4)
- SA Editor Judy Weil(2)
Most popular authors
(tracked in watchlists)
- Bespoke Investment Group(679)
- SA Editor Eli Hoffmann(413)
- Andrew Wilkinson(407)
- Richard Shaw(357)
- Market Folly(291)
Most commented on authors
- SA Editor Eli Hoffmann(19)
- Market Folly(12)
- Keith Robison(11)
- Richard Shaw(10)
- Zacks.com (7)
- Hedge Fund Tracking: Farallon Capital Management (Thomas Steyer), Q3 2008
- Generic Drug Price War Ramps Up
- Five Things Worth Remembering About Healthcare in 2009
- Hedge Fund Tracking: Eton Park Capital (Eric Mindich), Q3 2008
- FDA Calendar Update: High Hopes for Amgen's Bone Drug
- Hedge Fund Tracking: Moore Capital Management (Louis Bacon), Q3 2008
- Strong Dollar's Impact on Pharma vs. Generics
- Hedge Fund Tracking: Paulson & Co. (John Paulson), Q3 2008
- 11 Updated Stocks and the Sad Story They Tell
- New Healthcare Cost Containment Index
- What Are Some of the Best Hedge Fund Managers Doing?
- Teva Beats On Profits
- Bullish Outlook for Generic Drugs Post-Election
- Only Abatement of Risk Aversion Will Stop VIX from Further Fall - JP Morgan Strategist
- Best and Worst Performing S&P 500 Stocks, YTD
- Generic Drug Industry Outperforms Drug and Healthcare ETFs
- Biggest Gainers, Losers Since 9/29
- Overview and Analysis of the Global Generic Drug Industry
- Summer Surge for Pharma Powers IHE, but Concerns Remain
- Merger Watch: Barr Pharmaceuticals - Teva Pharmaceutical
- Sector and Stock Performance Since Oil's Peak
- Big Pharma’s Healthy Appetite for Acquisitions
- Board and Executive Compensation in S&P 500
- Watch for More Coming Biotech Acquisitions
- S&P 500's Best and Worst Net Income Change
- Gannon On Investing's July 2008 Blogger Roundtable
- Teva Buys Barr Pharmaceuticals
- Friday Options Update: MSFT, BAC, MIR, OSTK, GILD, BRL, MAT
- Wall Street Breakfast: Must-Know News
- Is Teva Looking to Buy Barr Pharmaceuticals?
- Wednesday Options Outlook: XLF, MSFT, BRL, CCL, ARM, BWA, PXP, VIX
- Barr and Mylan Invalidate Boehringer Ingelheim's Patent on Mirapex
- Wall Street Breakfast: Must-Know News
- Ortho-McNeil's Formulation Patent on Ultracet Declared Invalid
- Barr Labs Prevails Over Bayer in Yasmin Case
- Wall Street Breakfast: Must-Know News
- Drugmakers: Inflation Rate for Prescription Meds at 34-Year Low
- Biogenerics: Not Yet a Reality in the U.S.
- Denial of Certiorari in Tamoxifen Case Recommended by the Solicitor General
- Decision Imminent in Tamoxifen Petition on AstraZeneca, Barr Settlement
- Biotech Generics: Who Stands Where? - Barron's
Hedge Fund Jobs
Job Seekers: Search jobs by category, get job alerts by email or live feed, apply online See full list of jobs »
Employers: See all recruitment options, get applications online or by email Post a job »
Trading Center
- Free E-Newsletters
- About Seeking Alpha
- About Us
- Contact Us
- What's New
- Readers Feedback
- Advertise With Us
- Contributors
- Contribute an Article
- Feature Your Book
- Our Contributors
- Anonymous Contributions
- Dispute an Article?
- Legal
- Terms of Use
- Privacy
- Copyright